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Summary The roles of a self-completed symptom questionnaire and four biochemical markers ofdisease were
assessed to determine risk for gastric and colorectal cancer from within a hospital population and a random
population. Eight-six patients with cancer, 168 subjects with benign conditions of the stomach and large
bowel and 720 individuals from the community at large were investigated. Multivariate analyses of the
questionnaire and biochemical data were performed individually and in combination using a data set
comprising 54 cancer subjects, 80 patients with benign disease and 200 random individuals. The most
favourable predictive equation derived was then applied to the remaining data set to determine its efficacy. In
the primary analyses the questionnaire data identified 32 (60%) cancers successfully and using the biochemical
markers alone 36 (67%) patients were also correctly classified as cancer bearing. However, the combination of
the questionnaire and marker data improved the sensitivity for cancer to 50 cancers detected (92%) (P<0.02).
Using the predictive equation from this combination of data to identify risk in the second data set 28/32
(88%) cancers were correctly identified with only an 11% false positive rate. An 18 month follow-up for the
non-cancer group has to date revealed only one cancer (ca. pancreas).
In this limited study, multivariate analysis of questionnaire and biochemical marker data does successfully
identify individuals at 'high risk' of harbouring gastric or colorectal cancer within a symptomatic population
and may have a role in determining priority for investigation for a symptomatic individual.
There can often be considerable delay in the
diagnosis of gastrointestinal (GI) cancer in a
symptomatic population presenting to a clinician,
despite the availability of sophisticated methods
of investigation (MacAdam, 1979; Holliday &
Hardcastle, 1980). While it is desirable to investi-
gate all symptomatic patients to exclude neoplasia,
there has been a call to rationalise the way patients
are referred for investigation, particularly to
endoscopy units (Mann et al., 1983). Clearly some
simple method to select 'high risk' groups is
required so that priorities for investigation of
patients can be made and so reduce delay in the
diagnosis of GI cancer.
Unfortunately no such simple method exists.
Initially it was hoped that a serum tumour marker,
such as carcinoembryonic antigen (CEA), would
have sufficient sensitivity and specificity to detect
GI cancer preoperatively in a symptomatic
individual. The recent National Institute of Health
Concensus Report (1981) declared that CEA should
not be used as a preoperative investigative tool to
detect GI malignancy and no other individual
tumour marker has been found to be of value.
However, the investigation of combinations of CEA
and acute phase reactant proteins (APRPs) has
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shown that they may aid in prognosis for both
gastric (Rashid et al., 1982) and colorectal cancer
(Ward et al., 1977). This observation stimulated
Chu and colleagues (1982) to assess the com-
bination of CEA and alpha-l-acid glycoprotein
pre-operatively in patients with colorectal cancer,
where the sensitivity for detection of cancer
increased significantly but was associated with a
reduction in specificity. De Mello et al. (1983)
pursued this approach by using a panel of six non-
specific biochemical markers to define 'cancer risk'
preoperatively; by applying multivariate analysis
they identified 162 GI cancers (81%) with a false
positive rate of 16%. Further, Walker and Gray
(1983), applying discriminant analysis to a battery
of markers found that the combination of serum
protein hexose and CEA could significantly increase
the preoperative detection of colorectal cancer. In
addition Mann et al. (1983) have recently reported
the use of multivariate analysis of the symptom
complexes of patients presenting for endoscopy to
develop a scoring index which identifies priority for
investigation and 'risk' of upper GI disease.
We have incorporated both these approaches into
a study to assess: (a) the use of multivariate
analysis applied to four biochemical indicators of
disease: CEA, gamma glutamyl transpeptidase
(GGT), C-reactive protein (CRP) and alpha-l-acid
glycoprotein (AGP) to identify cancer risk; and (b)
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the role of symptom analysis with or without the
addition of potential tumour markers to define risk
for GI cancer.
Patients and methods
Eighty-six subjects with GI cancer, 168 with benign
GI disease and 720 individuals from the general
public were investigated (Table I). The group from
the population at large was included since it has
been shown by Jones (1976) and Thomson and
Heaton (1979) that many apparently normal
individuals may have present at any given time
symptoms suggestive of significant gastrointestinal
disease. Thus to produce a system to reduce over-
investigation of individuals it is necessary to take
account of the background prevalence of symptoms
within an age-matched population. Entry into this
group was determined by age, 50-70 years, and by
enrolment by the general parctitioner of individuals
felt to be free of active gastrointestinal disease.
Each individual was required to complete a
symptom questionnaire and give a 10ml sample of
blood. The blood was allowed to clot, centrifuged
at 3000r.p.m. and the serum stored at -25°C for
subsequent analysis.
Table I Details of study groups
Group No. Mean age Site ofdisease
Cancer 86 68y 57 Colorectal
29 Gastric
Benign 168 53.7y 88 Colorectal disease
80 Gastroduodenal disease
'Normal' 720 58.1 y No active GI disease
Questionnaire
The questionnaire comprised 41 questions, 18
relating to GI symptoms and 23 further questions
pertaining to previous health, social history and
pertinent epidemiological data. The format was
simple, requiring a tick in a box to represent a
positive or negative response. The questionnaire
had previously been validated on 144 individuals
and has been reported elsewhere (Chisholm et al.,
1985). In this survey only the 18 GI questions have
been used in the subsequent analyses.
Analytical methods
CEA was determined using Phadebas CEA Prist
kits supplied by Pharmacia Diagnostics AB
(Upsala, Sweden). Gamma glutamyl transpeptidase
(GGT) was measured at 37°C by the method of
Haesen et al. (1972) using a Technicon II Auto-
analyser. C-reactive protein (CRP) and alpha-l-acid
glycoprotein (AGP) were measured by single radial
immunodiffusion Mancini et al., 1965) using anti-
sera and standards obtained from Behringwerke,
Marburg, Koln, Germany.
Statistical analysis
A preliminary analysis of the relative frequency of
positive responses to each GI question was
performed using a x2 test to detect significantly
different response rates for cancer patients
compared to the remaining groups. Similarly, the
cumulative frequency distribution of each bio-
chemical variable was plotted and, by using the
95th percentile value of the benign group as a cut-
off point, the sensitivity and specificity of each
marker to detect cancer were determined.
A logistic discriminant analysis (Anderson, 1972;
Albert, 1982) has also been employed in this study
to determine which variables are significant in
discriminating between the cancer and non-cancer
subjects. A stepwise procedure was adopted in
which variables (4 tumour markers and 18 GI
questions) are added to the model sequentially and
at each step the statistical significance for each term
not already in the model is calculated. The most
significant variable at each step is added and when
no variable is significant at the 5% level the process
stops. Biochemical measurements underwent a
logarithmic transformation (log 10) and positive
responses to the questionnaire were accorded a
score of + 1 and a negative response -1. Sex was
coded as +1 for male and -1 for female. The
analysis was performed using the statistical package
BMDP81, subroutine PLR, on the University of
Leeds AMDAHL 470 computer.
To fit the model we used 54 cancer cases and the
non-cancer group comprised 80 benign and 200
control population (first set data). As more cases
were enrolled it was hoped that the model could be
applied prospectively, thus permitting a more
accurate impression of the validity of the model in
a clinical setting (second set data).
Results
The sensitivity and specificity for the individual
biochemical markers using an arbitrary cut-off
point equal to the 95th centile of the benign group
are shown in Table II. Thus the single most
sensitive agent was CRP with an overall detection
for cancer of 52%.
x2 analysis of the 18 GI questions revealed 6
questions which significantly distinguished between
cancer and non-cancer subjects (Table III).CANCER RISK IN A SYMPTOMATIC POPULATION
Table II Percentage of patients with a tumour marker value greater than the 95th
centile of the benign group
Cut offvalue Cancer (%)
Tumour marker (95th centile benign) Colorectal Gastric Normal (%)
CEA > 1OngmI-' 47.4 48.3 2.5
AGP > 1.4g 1-l 36.8 65 2.6
CRP > 12mgl'- 4.4 69 2.8
GGT >50Ul-1 14 10 2.1
Table III Percentage frequency of positive responses per question for
cancer and non-cancer groups
Cancer Non-cancera P value (X2 test)
Reduced appetite 56.7 29.78 0.0012
Weight loss 64.7 30.7 0.0001
Food sticking 33.3 24.6 0.0001
Nausea 24.0 42.0 0.02
Altered bowel frequency 71.9 37.8 0.0001
Altered stool appearance 62.7 36.7 0.0025
aNon-cancer=Patients with benign disease and normal individuals.
However 35% non-cancer bearing subjects had 3 or
more positive responses present.
We used the first set of data to fit a logistic
model to discriminate the cancer from the non-
cancer group. Using only the biochemical data, 36
(67%) of the 54 cancer patients were correctly
classified, with a false positive rate of only 5%. The
18 cancers missed by this simple discriminant
included S patients with liver metastases from
colorectal cancer and 2 patients with advanced
gastric cancer. A similar analysis of the 18 GI
questions correctly classified 60% cancers with a
5% false positive rate. In a logistic analysis using
both the questionnaire and biochemical data, 50
cancers (92%) were separated from the non-cancer
groups, with a similar 5% false positive rate (Table
IV). This is a significant improvement on both the
questionnaire and biochemical data when used
individually (P<0.02, x2 test). The cancers mis-




Biochemical markers 36 (67)a 95
Questionnaire 33 (60) 95
Markers plus questionnaire 50 (92) 95
aPercentage in parenthesis.
identified were 2 colorectal cancers (Dukes' stage
C+D) and 2 gastric cancers (stage II+IV).
The fitted model is determined by the
discriminant function (log to base 10): y=0.605
(sex) +0.112 (age) +2.73 log (CRP) +5.33 log
(CEA) -4.09 log (GGT) +1.05 (wt loss) +0.968
(bowel habit) +constant (8.4) and the probability
of cancer is then P=exp(y)/(l +exp(y)).
The 'optimal' cut-off point for these values to
indicate cancer is P>0.275.
By applying this criterion to the second set data,
28 of 32 cancers (88%) were selected but the
specificity fell to 89%. The 4 cancers misclassified
as low risk for cancer were all colorectal (Dukes' C).
Application of this type of analysis to the
patients with benign disease, lead to 26 of the 168
individuals being identified as at 'high risk' of
cancer. However, included in the 26 there were 4
subjects with gastric ulcer or polyps and 4 patients
with large colonic adenomata and villous polyps.
Thus the system detected further 'high-risk'
potentially premalignant conditions which clinicians
would wish to investigate.
Fifty-six subjects of the 720 individuals in the GP
study were classified by the analyses to be at high-
risk for cancer. Only seven were investigated but no
neoplasia was detected. In the remainder, raised
acute phase reactant proteins (APRPs) due to
upper respiratory tract infections (the reason for the
GP consultation) may have caused the high
probability value. To date, with a follow up of 18
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months, no cancers have been identified in these 56
subjects.
Discussion
The problems of using a single tumour marker for
cancer detection are again well demonstrated in this
study. Even by taking the 95th percentile value of
the patients with benign disease as the cut-off point
for CEA detecting cancer, there is still 2.5% of the
normal population with elevated CEA levels, whilst
the sensitivity for cancer was only 47%. However,
with a logistic analysis using the combination of
four biochemical markers, we have confirmed the
approach of de Mello et al. (1983) in that 36 (67%)
cancers were detected in the first analysis, with a
5% false positive rate.
The analysis of the symptoms showed that 35%
of the general population had at least three positive
GI responses in the questionnaire. Eleven per cent
had noticed rectal bleeding at some time (6%
within a year) and 27% had experienced episodes
of diarrhoea which somewhat dilutes these
symptoms as potential markers for GI malignancy.
Using the multivariate approach, only 60% cancers
were correctly classified, thus showing the
considerable overlap of symptoms between benign
disease and cancer bearing subjects. This raises
doubts concerning the validity of symptom complex
analysis to determine cancer risk.
Combining the questionnaire data and the
biochemical values, however, a significant improve-
ment in the diagnosis of cancer has been achieved
(P<0.02, x2 test). By demanding a cut-off point
which assured a high level of specificity in the first
data set, we feel that we have managed to reduce
the degree of false positivity that would normally
be expected in a second phase study. Thus the
recognition of 88% cancers with an 11% false
positive rate in the second data set using this
method is encouraging. It could be argued that by
accepting a low level of probability of cancer
(P<0.275) we have ensured a high sensitivity.
However, by wtilising a large number of controls we
have shown that few 'normal' individuals would be
selected for investigation despite the presence of
multiple symptoms in 30% of the population.
Furthermore, few of the benign disease group (15%)
would be selected for investigation, implying that
the cut off is satisfactory. The classification of
patients with gastric ulcers and polyps and
colorectal polyps into the high risk group for
cancer may be seen not as a failure of the system
but potentially useful to recognise a 'pre-malignant'
condition and would fit the significant disease
category of Mann et al. (1983).
The follow up of the 26 subjects with benign
disease who were labelled as 'high risk' has revealed
one cancer already. This individual with upper GI
symptoms who had negative barium meal and
gastroscopy, but re-presented six months later, was
found to have a carcinoma of the fundus of the
stomach. The probability of cancer at the first
presentation was 80% using the questionnaire and
tumour marker data. We await with interest the
outcome of those normal subjects who had a high
probability and were not investigated subsequently.
Such results in a preliminary study must always
be met with caution. Whilst the number of non-
cancer subjects used in this study is larger than
previous reports, the whole study is still small and
we would envisage a rather prolonged prospective
collection of data before evaluating the potential of
this approach. Further to miss six potentially
curable colorectal cancers and one curable gastric
cancer is not to be considered lightly. However, all
three symptomatic Dukes' A and 13 of 14 Dukes' B
colorectal cancers were detected. We would stress
that the objective is to identify 'risk' for cancer and
therefore to define priority for investigation when
dealing with a symptomatic population. Any
patient with persistent symptoms could easily be
referred sooner irrespective of the probability value.
The basic cost for this approach must be
considered as a balance between expenditure on
these tests versus any reduction in investigation
costs by reduced referral rates. The biochemical
analyses cost £5.00 per head (including labour but
excluding overheads), the brunt of which is the
price of the CEA kits. This could be offset by the
reduction in unnecessary investigations where the
probability ofcancer is extremely low.
In conclusion, we would suggest that neither
biochemical variables or symptom analysis alone
will define 'cancer risk' as accurately as the
combination of both in a multivariate analysis. We
would cautiously recommend further interest and
recommend this approach as a possible way of
using resources to identify those symptomatic
patients who should be fully investigated for
cancer.
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